Michael Casey Flanagan

US Patent:

D484883, Jan 6, 2004

Filed:

Oct 8, 2002

Appl. No.:

29/168848

Inventors:

Pascal Georges Metivier - Atlanta GA
Jonathan P. Payne - Lawrenceville GA
Arnon Alexander - Marietta GA
Michael T. Flanagan - Philadelphia PA

Assignee:

Onity, Inc. - Norcross GA

International Classification:

1402

US Classification:

D14436

US Patent:

D517439, Mar 21, 2006

Filed:

Dec 19, 2003

Appl. No.:

29/195984

Inventors:

Kevin Bruce Black - Roswell GA, US
John Detler Coleman - Philadelphia PA, US
Edmond John Dougherty - Wayne PA, US
Silvio Peter Eberhardt - Bennington VT, US
Matthew Anthony Ferris - Atlanta GA, US
Michael Thomas Flanagan - Philadelphia PA, US
Zoey Leslie Juhng - Philadelphia PA, US
Thomas Kondziolka - Chicago IL, US
Mathieu Dominic Daniel Turpault - Berwyn PA, US
Xavier Vinas - Philadelphia PA, US

Assignee:

SignalOne Safety, Inc. - Roswell GA

International Classification:

1005

US Classification:

D10106

US Patent:

20060269576, Nov 30, 2006

Filed:

May 27, 2005

Appl. No.:

11/140457

Inventors:

Peter Moldt - Rungsted Kyst, DK
Ove Pedersen - Ringsted, DK
Klaus Theobald - Paoli PA, US
Michael Flanagan - Kalamazoo MI, US

Assignee:

Curalogic, A/S - Copenhagen K

International Classification:

A61K 39/35
A61K 39/36

US Classification:

424275100

Abstract:

Methods and compositions are disclosed for the reduction of immune responses to an exogenous allergen. The reduction is obtained by pre-treatment or pre-conditioning, without injection, of a subject with the allergen so as to reduce immune responses in the subject upon additional exposure to the allergen. The invention is advantageously used in a variety of contexts, including seasonal allergies wherein pre-treatment or pre-conditioning is performed before the onset of the seasonal allergy.

US Patent:

20090214597, Aug 27, 2009

Filed:

May 19, 2006

Appl. No.:

11/915564

Inventors:

Peter Moldt - Rungsted Kyst, DK
Ove Pedersen - Ringsted, DK
Klaus Theobald - Paoli PA, US
Michael Flanagan - Kalamazoo MI, US

Assignee:

Curalogic A/S - Kobenhavn K

International Classification:

A61K 39/36
A61P 37/08

US Classification:

4242751

Abstract:

Methods and compositions are disclosed for the reduction of immune responses to an exogenous allergen. The reduction is obtained by pre-treatment or pre-conditioning, without injection, of a subject with the allergen so as to reduce immune responses in the subject upon additional exposure to the allergen. The invention is advantageously used in a variety of contexts, including seasonal allergies wherein pre-treatment or pre-conditioning is performed before the onset of the seasonal allergy.

US Patent:

20130217756, Aug 22, 2013

Filed:

Oct 25, 2011

Appl. No.:

13/881415

Inventors:

Mark Cancilla - Philadelphia PA, US
James John Cunningham - Wayne PA, US
Michael W. Flanagan - Menlo Park CA, US
Henry J. Haringsma - San Francisco CA, US
Denise M. Kenski - San Francisco CA, US
Matthew G. Stanton - Marlton NJ, US
Steven M. Stirdivant - Cary NC, US
Aarron T. Willingham - Mountain View CA, US

Assignee:

MERCK SHARP & DOHME CORP. - Rahway NJ

International Classification:

C07H 21/02

US Classification:

514 44 A, 536 245

Abstract:

The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.

US Patent:

20160264964, Sep 15, 2016

Filed:

Dec 30, 2015

Appl. No.:

14/984065

Inventors:

- Cambridge MA, US
James John Cunningham - West Point PA, US
Michael William Flanagan - Menlo Park CA, US
Henry J. Haringsma - San Francisco CA, US
Denise M. Kenski - San Francisco CA, US
Matthew G. Stanton - Rahway NJ, US
Steven M. Stirdivant - Doylestown PA, US
Aarron T. Willingham - San Francisco CA, US

Assignee:

SIRNA THERAPEUTICS, INC. - Cambridge MA

International Classification:

C12N 15/113

Abstract:

The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.